Trinity Biotech

Trinity Biotech Liabilities

The The Liabilities of Trinity Biotech (TRIB) as of Nov 20, 2026 is 177.15 M USD. In the previous year, The Liabilities was 138.47 M USD — a change of 27.93% (higher).

Liabilities

177.15 MUSD

YoY

27.93%

Last updated:

In 2025, Trinity Biotech's total liabilities amounted to 177.15 M USD, a 27.93% difference from the 138.47 M USD total liabilities in the previous year.

The Trinity Biotech Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
107.18 M USD
Jan 1, 2019
126.36 M USD
Jan 1, 2020
132.62 M USD
Jan 1, 2021
119.21 M USD
Jan 1, 2022
94.28 M USD
Jan 1, 2023
83.38 M USD
Jan 1, 2024
138.47 M USD
Jan 1, 2025
177.15 M USD
The Trinity Biotech Liabilities history
YEARLiabilitiesYoY
177.15 MUSD+27.93%
138.47 MUSD+66.06%
83.38 MUSD-11.56%
94.28 MUSD-20.92%
119.21 MUSD-10.11%
132.62 MUSD+4.95%
126.36 MUSD+17.89%
107.18 MUSD-15.88%
127.42 MUSD-9.55%
140.87 MUSD-2.90%
145.07 MUSD+216.30%
45.87 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Trinity Biotech's Liabilities

Trinity Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Trinity Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Trinity Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Trinity Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Trinity Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Trinity Biotech stock

The Liabilities of Trinity Biotech is 177.15 M USD in 2025.

The Liabilities of Trinity Biotech changed from 138.47 M USD to 177.15 M USD, representing a 27.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech